TetraScience’s Post

Future of the global cell and gene therapy manufacturing service market looks promising with opportunities in cell processing, cell banking, process development, fill and finish operations, analytical and quality testing, raw material testing, and vector production. Major growth drivers include growing number of cancer cases and rare diseases, and increasing research and development spending in pharmaceutical companies. Key players such as Lonza, Bluebird Bio, and Catalent are implementing influential marketing approaches. The global cell and gene therapy manufacturing service market is expected to reach an estimated $21 billion by 2028 with a CAGR of 22.1% from 2023 to 2028. Read more: https://lnkd.in/gxmed4Fr. For any questions, feel free to reach out at [email protected]. #cellandgenetherapymanufacturingservicemarket #marketresearch #lucintel

Phase II readouts from 4D Molecular Therapeutics and REGENXBIO Inc. (with another on deck from Adverum Biotechnologies) suggest that #genetherapies may shake up the treatment of #wetAMD – and the established order of anti-VEGF therapies along with it. To learn how gene therapy could reshape the AMD landscape and what key questions still need to be answered, we are asking an expert. Learn more here: https://lnkd.in/dfgWB9NY #biotechnology #clinicalresearch #clinicaltrials #drugdevelopment #FDA #genetherapy #pharmaceuticals

Cell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 - Comprehensive Study by The Insight Partners. #manufacturing #CellandGeneTherapyManufacturingServicesMarket #ComprehensiveStudy #InsightPartners

At my first gene therapy conference, which I attended in 2017, digital PCR was almost not mentioned. Today, digital PCR has become an indispensable tool in gene therapy research and manufacturing. On April 23rd, I am hosting a webinar with Stilla Technologies about The Impact of Digital PCR on Quantification in Biopharma Research And Manufacturing. You can register here: https://hubs.la/Q02rjMDP0 Hope to see you there! #biopharma #genetherapy #webinar

#Webinar now available on demand! Case study: becoming the first GMP-certified cell and gene therapy manufacturing facility in Thailand Kitipong Uaesoontrachoon (Chief Scientific Officer, Genepeutic Bio Co., Ltd.) discusses the establishment of the first #GMP-certified cell and #genetherapy manufacturing facility in Thailand. He provides insights into the importance of PD optimization, closing and automating workflows, training, project management, tech transfer, and the key lessons learned along the way. Watch this webinar at your convenience to: • Understand how to overcome some of the hurdles to achieve #GMPmanufacturing • Learn more about process development capabilities to better support cGMP manufacturing • Gain industry-relevant insight from a case study for developing GMP-compliant facilities in Asia • Discover how to apply lessons learned to help streamline your capacity expansion project to support patients in need

The biomanufacturing world is evolving rapidly, with cell and gene therapy at its heart, reshaping everything from production to real estate strategies. As demand for specialized facilities surges, the industry is rallying around strategic investments and innovative collaborations to meet these new challenges. This is a great 7-minute read! #Biomanufacturing

Interested in discovering how the Biopharmaceutical Analysis Training Laboratory (BATL) at Northeastern University achieved efficiencies in cell and gene therapy manufacturing through collaboration with Thermo Fisher Scientific? Download our case study to learn more.

Interested in discovering how the Biopharmaceutical Analysis Training Laboratory (BATL) at Northeastern University achieved efficiencies in cell and gene therapy manufacturing through collaboration with Thermo Fisher Scientific? Download our case study to learn more.

e-Lesson of the day: 🔎 ATMP MANUFACTURING - CELL AND GENE THERAPIES This Digital Learning Module is designed for personnel who require an overview of the nature and function of cell and gene therapy products, their modes of manufacture (with a particular focus on autologous and allogeneic therapies), and the associated technical challenges and regulatory requirements. Follow SKILLPAD - digital learning for life sciences on LinkedIn at https://lnkd.in/ejd-z5Am for more news and updates. ATMP MANUFACTURING - CELL AND GENE THERAPIES covers these Learning Objectives: ✅ Define “Advanced Therapy Medicinal Product” (ATMP) ✅ Explain the difference between ATMPs and ‘traditional’ biopharmaceutical products ✅ Explain the difference between gene and cell therapies ✅ Describe the biological functionality of cell therapies ✅ Describe the biological functionality of gene therapies ✅ Distinguish between autologous and allogeneic therapeutic approaches ✅ List the main steps in manufacturing autologous therapies ✅ List the main steps involved in manufacturing allogeneic therapies ✅ Describe the challenges associated with ATMP manufacturing, and in general terms how these challenges might be overcome Description and screenshots here: https://lnkd.in/e96Km6KV Schedule a DEMO by contacting [email protected] #pharma #biotech #biologics #biopharma #biopharmaceuticals #lifesciences #genetherapies #atmp

Highly recommend attending this upcoming BioTechLogic webinar, which will take place in 2 weeks! This is an excellent opportunity to gain insight into establishing a strong 💪 Gene Therapy Process Control Strategy. While this webinar is geared towards GT, much of the content is translatable to other sectors of biotech. 💊🧬🧫🩸🦠💉 So, if you have any interest in learning more about Process Control Strategy considerations, use the link in the post below👇 to sign up!